Which ACE Inhibitor to Initiate for Hypertension
For hypertension, any of the evidence-based ACE inhibitors (lisinopril, enalapril, ramipril, or perindopril) can be initiated, with lisinopril being the most practical choice due to once-daily dosing and consistent 24-hour blood pressure control. 1
Starting Doses and Titration
The evidence-based ACE inhibitors with proven cardiovascular outcomes include 1:
- Lisinopril: Start 2.5-5 mg once daily → Target 20-40 mg once daily
- Enalapril: Start 2.5 mg twice daily → Target 10-20 mg twice daily
- Ramipril: Start 1.25-2.5 mg once daily → Target 10 mg once daily
- Perindopril: Start 2 mg once daily → Target 8-16 mg once daily
Titration approach: Initiate at low doses and increase gradually every 1-2 weeks if tolerated, aiming for target doses used in clinical trials 1. If target doses cannot be achieved due to side effects, intermediate doses still provide benefit with only small differences in efficacy between low and high doses 1.
Key Monitoring Parameters
Baseline assessment 1:
- Serum creatinine and estimated GFR
- Serum potassium
- Blood pressure
Follow-up monitoring 1:
- Recheck creatinine, potassium, and blood pressure within 1-2 weeks of initiation
- Repeat after each dose increase
- Monitor periodically thereafter, especially in patients with:
- Pre-existing hypotension (SBP <80 mmHg)
- Diabetes mellitus
- Baseline creatinine >3 mg/dL
- Baseline potassium >5.0 mEq/L
- Concurrent use of potassium supplements
Critical Safety Considerations
Acceptable changes after initiation 2:
- Modest decrease in eGFR and increase in creatinine are expected
- Discontinue if: eGFR decreases >15%, creatinine increases >20%, or hyperkalemia develops
Absolute contraindications 3, 4, 1:
- History of angioedema (lifetime avoidance of all ACE inhibitors)
- Pregnancy or planning pregnancy
- Bilateral renal artery stenosis
Use with extreme caution if 1:
- Systolic blood pressure <80 mmHg
- Serum creatinine >3 mg/dL
- Serum potassium >5.0 mEq/L
Common Pitfalls and Management
Cough 3, 4: Occurs in 5-10% of patients. Exclude other causes (especially pulmonary congestion) before attributing to ACE inhibitor. If persistent and troublesome despite encouragement to continue, switch to ARB rather than discontinuing RAAS blockade entirely.
Angioedema 3, 4: Occurs in <1% but more frequent in Black patients. Life-threatening—requires permanent discontinuation of all ACE inhibitors. ARBs can be considered as alternative but use with extreme caution as cross-reactivity can occur.
Hypoglycemia 2: ACE inhibitors may precipitate hypoglycemia in patients taking glucose-lowering medications—counsel patients accordingly.
Avoid abrupt withdrawal 1: Can lead to clinical deterioration.
Special Populations
Non-Black patients with hypertension 5, 6, 7: ACE inhibitors or ARBs are preferred first-line agents.
Black patients with hypertension 5: Thiazide-type diuretics or calcium channel blockers are preferred as initial monotherapy; ACE inhibitors can be added as second-line therapy.
Heart failure with reduced ejection fraction 8, 1: ACE inhibitors are mandatory (Class I recommendation) for all patients with LVEF <40% unless contraindicated, used in combination with beta-blockers.
Post-myocardial infarction 9, 10: ACE inhibitors should be started and continued indefinitely, especially with LVEF <40%.
Diabetes with albuminuria 11: ACE inhibitors are first-line for patients with urinary albumin-to-creatinine ratio ≥30 mg/g creatinine, titrated to maximum tolerated doses.
Combination Therapy Considerations
Never combine 3, 4, 6, 7: ACE inhibitor + ARB + renin inhibitor (Class III Harm recommendation due to increased risk of hypotension, renal dysfunction, and hyperkalemia without additional benefit).
- ACE inhibitor + thiazide-type diuretic (reduces hypokalemia risk)
- ACE inhibitor + dihydropyridine calcium channel blocker (reduces leg edema from CCB)